Another CT from those declared at ESC 2018... Yet once again the inadequacies of RCT's gets exposed! Febuxostat is good ... no, it is not ... yes, it is ... no, it is actually harmful ... no, it is safe.
"Contradictory Results" ... this has been one of the inadequacies that have been pointed out for RCT's. That is one of the reasons why sensible Clinicians are, in addition to RCT's, are also embracing the discipline of Clinical Reason rather than being compulsively dependent on RCT's ONLY. The study FREEDOM , summarized below, once again exonerates a molecule that has long been proved to be beneficial in spite of facing flak from some studies. NAME of RCT: FREEDOM OBJECTIVE: Study impact of reducing hyperuricemia in elderly on CV, Cerebral & Renal events DESIGN : Randomized, Comparative (Allopurinol), Parallel Patient Population : n = 1,070 ... Aged = =>65 yrs ... High-risk for CV,…
